Relmada Therapeutics, Inc.

Stage 4 · Declining · week 8

As of Oct 22, 2026, Relmada Therapeutics is in Stage 4, the downtrend phase, now in week 8 (since Sep 1, 2026). It closed at $3.29, 58.1% below its 52-week high and below its 200-day average, which is falling.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. More about the company

$3.29

+2.49% today

$351M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is RLMD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 15w

S4 21w

S1 16w

S2 24w

S2 15w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 1w → S1 6w → S2 6w → S3 8w → S2 15w → S3 6w → S4 7w → S1 3w → S4 9w → S1 6w → S4 21w → S1 16w → S4 2w → S2 24w → S3 2w → S2 15w → S3 10w → S4 7w current

Total tracked: 165 weeks across 18 stage runs.

RLMD among Biotechnology93rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…93	RLMDRelmada Therapeutics, Inc.	Stage 4 · wk 8	85	−13.0%

vs 52W High

-58.1%

$2.10 lo$7.86 hi

58.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 8

1w13w26w

Week 8, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-38.9%

200 DMA: $5.38 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

5.24x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-13.0%

-36.5%

-54.6%

YTD

-24.7%

+46.9%

Scan Membership

Breakout Watch

Latest: 2024-01-10

9 appearances in last 60 days. First seen: 2018-11-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 8 · Vol 5.24x

2026-10-21S4

Wk 8 · Vol 1.30x

2026-10-20S4

Wk 7 · Vol 0.60x

2026-10-19S4

Wk 7 · Vol 0.59x

2026-10-16S4

Wk 7 · Vol 1.02x

2026-10-15S4

Wk 7 · Vol 0.73x

2026-10-14S4

Wk 7 · Vol 1.09x

2026-10-13S4

Wk 6 · Vol 1.15x

2026-10-12S4

Wk 6 · Vol 1.14x

2026-10-09S4

Wk 6 · Vol 1.41x

2026-10-08S4

Wk 6 · Vol 1.55x

2026-10-07S4

Wk 6 · Vol 1.23x

Moving averages & range

50 DMA

$4.01

200 DMA

$5.38

52W High

$7.86

52W Low

$2.10

5D Low

$3.10

Resistance levels (recent highs)

20d High

$3.83

60d High

$5.47

120d High

$7.86

250d High

$7.86

Next resistance

+16.4%

to 20d High

ROE

-55.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.7

Relmada Therapeutics: quick answers

What stage is Relmada Therapeutics in?

As of Oct 22, 2026, Relmada Therapeutics (RLMD) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 1, 2026 and is in week 8. What the four stages mean

Is Relmada Therapeutics in an uptrend?

No. Relmada Therapeutics is in a Stage 4 downtrend. It trades 38.9% below its 200-day average, which is falling.

How far is Relmada Therapeutics from its 52-week high?

Relmada Therapeutics closed at $3.29 on Oct 22, 2026, 58.1% below its 52-week high of $7.86. Its 52-week low is $2.10.

How has Relmada Therapeutics performed over the past year?

As of Oct 22, 2026, Relmada Therapeutics is up 46.9% over the past year and down 24.7% so far in 2026.

Which sector and industry is Relmada Therapeutics in?

Relmada Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.